UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
||||||
SCHEDULE
13D/A
Under
the Securities Exchange Act of 1934
|
||||||
(Amendment
No.
|
1
|
)*
|
||||
BioVeris
Corporation
|
||||||
(Name
of Issuer)
|
||||||
Common
Stock, $0.001 par value per share
|
||||||
(Title
of Class of Securities)
|
||||||
090676107
|
||||||
(CUSIP
Number)
|
||||||
Roche
Holding Ltd
Grenzacherstrasse
124
CH-4070
Basel
Switzerland
+41-61-688-1111
|
||||||
(Name,
Address and Telephone Number of Person Authorized to
Receive
Notices and Communications)
|
||||||
May
2, 2007
|
||||||
(Date
of Event which Requires Filing of this Statement)
|
||||||
If
the filing person has previously filed a statement on Schedule 13G
to
report the acquisition that is the subject of this Schedule 13D,
and is
filing this schedule because of §§240.13d-1(e), 240.13d-l(f) or
240.13d-l(g), check the following box. o
|
||||||
*The
remainder of this cover page shall be filled out for a reporting
person’s
initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information
which
would alter disclosures provided in a prior cover page.
|
||||||
The
information required on the remainder of this cover page shall not
be
deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions
of
the Act (however, see the Notes).
|
||||||
This
form corrects certain information that was contained in the Schedule
13D
filed by Roche Holding Ltd with the United States Securities and
Exchange
Commission on April 12, 2007.
|
CUSIP
No.
090676107
|
||||
1.
|
Names
of Reporting Persons.
I.R.S.
Identification Nos. of above persons (entities only).
Roche
Holding Ltd
|
|||
2.
|
Check
the Appropriate Box if a Member of a Group (See Instructions)
(a)
o
|
|||
3.
|
SEC
Use Only
|
|||
4.
|
Source
of Funds (See Instructions)
N/A
|
|||
5.
|
Check
if Disclosure of Legal Proceedings Is Required Pursuant to Items
2(d) or
2(e) o
|
|||
6.
|
Citizenship
or Place of Organization
Switzerland
|
|||
NUMBER
OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON WITH |
7.
|
Sole
Voting Power
0
|
||
8.
|
Shared
Voting Power
5,597,437
shares of Common Stock (including 332,000 shares subject to outstanding
options which amount includes vested and unvested options)(1)
|
|||
9.
|
Sole
Dispositive Power
0
|
|||
10.
|
Shared
Dispositive Power
0
|
|||
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
5,597,437
shares of Common Stock(1)
|
|||
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares (See
Instructions) o
|
|||
13.
|
Percent
of Class Represented by Amount in Row (11)
19.3%
(excluding underlying options)
|
|||
14.
|
Type
of Reporting Person (See Instructions)
CO
|
ROCHE
HOLDING LTD
|
|||
By:
|
/s/ Bruno Maier
|
||
Name: Bruno
Maier
|
|||
Title: Director
|
|||
By:
|
/s/ Beat Kraehenmann
|
||
Name: Beat
Kraehenmann
|
|||
Title: Director
|